Marilynn Marchione from the Associated Press asked a good question in her article today:
How does a drug go from blockbuster to bust?
How can big safety issues go undetected in medicines taken by millions of people for many years, as happened this week with the diabetes pill Avandia and a few years ago with the painkiller Vioxx?
Here’s a three-letter hint: the FDA. As long as the FDA has a vested financial interest in helping drug companies bring product to market, we will see these scenarios for years to come.
Isn’t it ironic that the FDA won’t allow the importation of drugs from Canadian pharmacies due to “safety reasons,” but will allow a drug to stay on the market that increases a patient’s risk of heart attack by 43 percent?
The simple answer to Marilynn’s question is this: FOLLOW THE MONEY.